Your browser doesn't support javascript.
loading
High-Risk Histopathological Features of Retinoblastoma following Primary Enucleation: A Global Study of 1426 Patients from 5 Continents.
Kaliki, Swathi; Vempuluru, Vijitha S; Bakal, Komal Rajendra; Dorji, Samten; Tanna, Vishakha; Shields, Charlotte N; Fallon, Samuel J; Raval, Vishal; Ahmad, Alia; Mushtaq, Asma; Hussain, Mahvish; Yousef, Yacoub A; Mohammad, Mona; Roy, Soma Rani; Huque, Fahmida; Tatiana, Ushakova; Yuri, Serov; Vladimir, Polyakov; Zambrano, Sandro Casavilca; Alarcón-León, Sandra; Valdiviezo-Zapata, Cinthya; Vargas-Martorellet, Maria; Gutierrez-Chira, Cynthia; Buitrago, Mario; Ortiz, Joana Sánchez; Diaz-Coronado, Rosdali; Tripathy, Devjyoti; Rath, Suryasnata; Patil, Gaurav; Berry, Jesse L; Pike, Sarah; Brown, Brianne; Tanabe, Mika; Frenkel, Shahar; Eiger-Moscovich, Maya; Pe'er, Jacob; Shields, Carol L; Eagle, Ralph C; Laiton, Andrea; Velasco, Ana Maria; Vega, Katherine; DeSimone, Joseph; Bejjanki, Kavya Madhuri; Kapoor, Anasua Ganguly; Venkataraman, Anusha; Bryant, Victoria; Reddy, M Ashwin; Sagoo, Mandeep S; Hubbard, G Baker; Azarcon, Corrina P.
Afiliación
  • Kaliki S; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Vempuluru VS; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Bakal KR; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Dorji S; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Tanna V; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Shields CN; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Fallon SJ; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Raval V; The Operation Eyesight Institute for Eye Cancer, LV Prasad Eye Institute, Hyderabad, India.
  • Ahmad A; Children Hospital, Lahore, Pakistan.
  • Mushtaq A; Children Hospital, Lahore, Pakistan.
  • Hussain M; Children Hospital, Lahore, Pakistan.
  • Yousef YA; King Hussein Cancer Center, Amman, Jordan.
  • Mohammad M; King Hussein Cancer Center, Amman, Jordan.
  • Roy SR; Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.
  • Huque F; Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.
  • Tatiana U; Department of Surgical Methods of Treatment with chemotherapy No. 1 (Head and Neck Tumors), N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.
  • Yuri S; L.A. Durnov Department of Pediatric Oncology of the Russian Medical Academy of Continuing Professional Education, Moscow, Russian Federation.
  • Vladimir P; Department of Surgical Methods of Treatment with chemotherapy No. 1 (Head and Neck Tumors), N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.
  • Zambrano SC; Department of Surgical Methods of Treatment with chemotherapy No. 1 (Head and Neck Tumors), N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation.
  • Alarcón-León S; L.A. Durnov Department of Pediatric Oncology of the Russian Medical Academy of Continuing Professional Education, Moscow, Russian Federation.
  • Valdiviezo-Zapata C; Department of ENT Diseases of the Faculty of Pediatrics of the Federal State Educational Institution of Higher Education of N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation.
  • Vargas-Martorellet M; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Gutierrez-Chira C; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Buitrago M; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Ortiz JS; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Diaz-Coronado R; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Tripathy D; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Rath S; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Patil G; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Berry JL; Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Pike S; LV Prasad Eye Institute, Bhubaneswar, India.
  • Brown B; LV Prasad Eye Institute, Bhubaneswar, India.
  • Tanabe M; LV Prasad Eye Institute, Bhubaneswar, India.
  • Frenkel S; Children's Hospital Los Angeles & USC Roski Eye Institute, Los Angeles, USA.
  • Eiger-Moscovich M; Keck School of Medicine, Los Angeles, USA.
  • Pe'er J; Children's Hospital Los Angeles & USC Roski Eye Institute, Los Angeles, USA.
  • Shields CL; Keck School of Medicine, Los Angeles, USA.
  • Eagle RC; Children's Hospital Los Angeles & USC Roski Eye Institute, Los Angeles, USA.
  • Laiton A; Keck School of Medicine, Los Angeles, USA.
  • Velasco AM; Kyushu University, Fukuoka, Japan.
  • Vega K; Hadassah Medical Center, Jerusalem, Israel.
  • DeSimone J; Hadassah Medical Center, Jerusalem, Israel.
  • Bejjanki KM; Hadassah Medical Center, Jerusalem, Israel.
  • Kapoor AG; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, USA.
  • Venkataraman A; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, USA.
  • Bryant V; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, USA.
  • Reddy MA; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, USA.
  • Sagoo MS; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, USA.
  • Hubbard GB; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, USA.
  • Azarcon CP; LV Prasad Eye Institute, Vijayawada, India.
Retina ; 2024 Aug 14.
Article en En | MEDLINE | ID: mdl-39151183
ABSTRACT

PURPOSE:

To evaluate high-risk histopathological features (HRHF) following primary enucleation of eyes with retinoblastoma (RB) and assess the patient outcomes across continents.

METHODS:

Retrospective study of 1426 primarily enucleated RB eyes from five continents.

RESULTS:

Of all, 923 (65%) were from Asia (AS), 27 (2%) from Australia (AUS), 120 (8%) from Europe (EUR), 162 (11%) from North America (NA), and 194 (14%) from South America (SA). Based on the continent (AS vs. AUS vs. EUR vs. NA vs. SA), the histopathology features included massive choroidal invasion (31% vs. 7% vs. 13% vs. 19% vs. 27%, p=0.001), post-laminar optic nerve invasion (27% vs. 0% vs. 16% vs. 21% vs. 19%, p=0.0006), scleral infiltration (5% vs. 0% vs. 4% vs. 2% vs. 7%, p=0.13), and microscopic extrascleral infiltration (4% vs. 0% vs. <1% vs. <1% vs. 4%, p=0.68). Adjuvant chemotherapy with/without orbital radiotherapy was given in 761 (53%) patients. Based on Kaplan-Meier estimates in different continents (AS vs. AUS vs. EUR vs. NA vs. SA), the 6-year risk of orbital tumor recurrence was 5% vs. 2% vs. 0% vs. 0% vs. 12% (p<0.001), systemic metastasis was reported in 8% vs. 5% vs. 2% vs. 0% vs. 13% (p=0.001), and death in 10% vs. 3% vs. 2% vs. 0% vs. 11% (p<0.001) patients.

CONCLUSION:

There is a wide variation in the infiltrative histopathology features of RB across continents, resulting in variable outcomes. SA and AS had a higher risk of orbital tumor recurrence, systemic metastasis, and death compared to AUS, EUR, and NA.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Retina Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Retina Año: 2024 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos